Ardelyx President and CEO Sells 41,000 Shares for $243,000

Transaction and post-transaction values based connected March 16, 2026 weighted mean merchantability terms of $5.84.

• What was the operation of this transaction, and did it impact derivative securities?
  This filing reflects an enactment workout for 20,833 shares, instantly followed by the merchantability of 41,666 shares of communal stock, highlighting the usage of equity compensation arsenic portion of ongoing liquidity management.

• How did this merchantability comparison successful size to Michael Raab's caller trading activity?
  The merchantability matched the caller period's median transaction size of 41,666 shares (from October 2024 to March 2026), indicating a unchangeable and regular cadence successful enactment with Raab's 10b5-1 plan.

• What is the interaction connected Raab's remaining ownership and capableness for aboriginal sales?
  After this transaction, Raab holds 1,816,448 shares straight and 25,364 shares indirectly, and retains 374,168 banal options, providing continued vulnerability and capableness for aboriginal equity-based compensation events.

• Is determination immoderate denotation of acceleration, moderation, oregon deviation from humanities commercialized sizes?
  Trade sizes person remained accordant arsenic disposable capableness has decreased, with this transaction representing 2.21% of Raab's full holdings, akin to respective anterior events, and reflecting regular portfolio absorption alternatively than a alteration successful intent.

* 1-year show is calculated utilizing March 16, 2026 arsenic the notation date.

• Offers proprietary medicines targeting gastrointestinal and cardiorenal diseases, with tenapanor arsenic the pb merchandise addressing irritable bowel syndrome with constipation and hyperphosphatemia successful chronic kidney illness patients.

• Generates gross done merchandise income and licensing agreements with planetary partners for cause commercialization.

• Serves healthcare providers and patients successful the United States and planetary markets, focusing connected those with gastrointestinal and kidney-related conditions.

Ardelyx is simply a biotechnology institution specializing successful the improvement and commercialization of innovative therapies for gastrointestinal and cardiorenal diseases. The institution leverages a pipeline of proprietary compounds, with tenapanor arsenic its flagship product, to code important unmet needs successful chronic kidney illness and related disorders. Strategic partnerships successful cardinal planetary markets and a focused attack to specialty therapeutics underpin Ardelyx's competitory positioning wrong the healthcare sector.